TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
ALDX

Aldeyra Therapeutics, Inc.

Healthcare · Biotechnology

0.5603$ -15.0% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Aldeyra Therapeutics, Inc. (ALDX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 81.1% of the shares are freely tradable; institutional investors hold 62.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 62.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 3.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 81.1%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 5.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 60Mio.

Largest Shareholders

Institutions

Institutions ALDX
Name Stake (%) Shares Change (%) Date
Knoll Capital Management LP 9.08 5,475,516 +0.0 06/30/2026
AQR Capital Management LLC 6.22 3,751,558 +32.6 06/30/2026
Kingdon Capital Management LLC 4.40 2,652,315 +23.2 06/30/2026
Vanguard Capital Management, LLC 3.92 2,361,796 -0.1 06/30/2026
D. E. Shaw & Co LP 3.22 1,940,338 +38.2 06/30/2026
Marshall Wace Asset Management Ltd 2.50 1,506,974 +1,062.0 06/30/2026
683 Capital Management LLC 2.49 1,500,000 -2.0 03/31/2026
Jane Street Group LLC 2.28 1,375,115 +41.9 06/30/2026
BlackRock Inc 2.08 1,257,243 -66.6 06/30/2026

Funds

Funds ALDX
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.96 1,784,433 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?